Over the last 7 days, the United States market has experienced a 1.8% drop, yet it has shown resilience with an 11% rise over the past year and anticipated earnings growth of 17% per annum in the coming years. In this context, stocks that combine high growth potential with strong insider ownership can be particularly appealing as they suggest confidence from those closest to the company's operations and strategy.
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 14.0% | 70.2% |
| Standard Nuclear (STDN) | 18.8% | 64.2% |
| Sable Offshore (SOC) | 11.3% | 71.3% |
| Precigen (PGEN) | 11.7% | 54% |
| Nu Holdings (NU) | 23.1% | 22.2% |
| Karman Holdings (KRMN) | 13.6% | 56.4% |
| Himax Technologies (HIMX) | 29.1% | 70.2% |
| Figure Technology Solutions (FIGR) | 21.4% | 33.1% |
| Energy Vault Holdings (NRGV) | 10.5% | 67.3% |
| Almonty Industries (ALM) | 10.8% | 57.6% |
Let's dive into some prime choices out of the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening diseases in the United States, with a market cap of $253.33 million.
Operations: The company's revenue is primarily generated from its biotechnology startups segment, totaling $25.52 million.
Insider Ownership: 16.1%
Abeona Therapeutics is experiencing significant revenue growth, forecasted at 42.2% annually, outpacing the US market average of 13.3%. Despite recent losses, the company is expected to become profitable within three years. Insider transactions show more shares bought than sold recently, indicating confidence in its prospects. The launch of ZEVASKYN for treating recessive dystrophic epidermolysis bullosa marks a significant milestone, with new treatment centers established and additional reimbursement support secured from Medicare & Medicaid Services.
Simply Wall St Growth Rating: ★★★★★☆
Overview: BillionToOne, Inc. is a precision diagnostics company focused on developing molecular diagnostics, with a market cap of $4.63 billion.
Operations: The company's revenue primarily comes from its Medical Labs & Research segment, which generated $397.41 million.
Insider Ownership: 10.6%
BillionToOne, Inc. is experiencing robust growth, with revenue projected to increase at 20.6% annually, surpassing the US market average of 13.3%. The company recently turned profitable and anticipates annual earnings growth of 33.7%, significantly outpacing the broader market's 16.9%. Recent product innovations like Northstar Origin and Northstar Response highlight its advancements in liquid biopsy technology, enhancing diagnostic capabilities without requiring tissue samples and addressing key clinical challenges in oncology diagnostics.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: RingCentral, Inc. is a cloud business communication services provider offering an integrated platform for various communication needs, with a market cap of approximately $6.30 billion.
Operations: The company's revenue segment is primarily derived from Internet Software & Services, totaling approximately $2.58 billion.
Insider Ownership: 10%
RingCentral is positioned for significant earnings growth, with forecasts indicating a 43.21% annual increase, surpassing the US market average. Despite high debt levels and volatile share prices, the company trades at 55.1% below estimated fair value and recently became profitable. Strategic partnerships in Italy and New Zealand expand its AI-driven communications platform globally. Recent innovations include ChatGPT plugins enhancing productivity through advanced data integration, signaling a focus on AI-powered business solutions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com